title: Immunotoxicological effects of piperine in mice.
abstract: The immunotoxicological effects of piperine were investigated in Swiss male mice, gavaged at a dose of 1.12, 2.25 or 4.5 mg/kg body weight for five consecutive days. All the dose levels had no overt toxic effect and the liver gained weight normally. Treatment at highest dose, however, resulted in significant decrease in the weight of spleen, thymus and mesenteric lymph nodes, but not of peripheral lymph nodes. All the dose levels suppressed the cellular population of lymphoid organs, except for the spleen, where the doses of 1.12 and 2.25 caused an increase. Haematologically, doses of 2.25 and 4.5 mg/kg caused a significant reduction in total leucocyte counts and differential leucocyte counts showed an increase in the percentage of neutrophils. The higher doses of 2.25 and 4.5 mg/kg suppressed the mitogenic response of B-lymphocyte to lipopolysaccharide. The number of primary antibody (IgM) forming cells in the spleen and the level of primary antibody in serum, was decreased. The doses of 1.12 and 2.25 mg/kg suppressed the mitogenic response of T-lymphocytes to phytohaemagglutinin and the nitroblue tetrazolium (NBT) dye reducing activity of peritoneal exudate cells (PECs). Since the lowest dose of 1.12 mg of piperine per kg body weight had no immunotoxic effect, it may be considered as immunologically safe "no observed adverse effect level (NOAEL)" dose.
authors.affiliation: Immunotoxicology Laboratory, Industrial Toxicology Research Centre, M.G. Marg, P.O. Box 80, Lucknow 226001, India.
authors.forename: Ram K S
authors.initials: RK
authors.lastname: Dogra
authors.forename: Santosh
authors.initials: S
authors.lastname: Khanna
authors.forename: Ravi
authors.initials: R
authors.lastname: Shanker
mesh_terms: D000470:Alkaloids; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D052117:Benzodioxoles; D001772:Blood Cell Count; D006462:Hemolytic Plaque Technique; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects*; D007075:Immunoglobulin M / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology; D008198:Lymph Nodes / Q000166:cytology / Q000276:immunology; D008297:Male; D051379:Mice; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D009580:Nitroblue Tetrazolium; D010587:Phagocytosis / Q000187:drug effects; D010835:Phytohemagglutinins / Q000494:pharmacology; D010880:Piperidines / Q000633:toxicity*; D053284:Polyunsaturated Alkamides; D012756:Sheep / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013950:Thymus Gland / Q000166:cytology / Q000187:drug effects / Q000276:immunology
chemical_list: D000470:Alkaloids; D052117:Benzodioxoles; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D010835:Phytohemagglutinins; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D009580:Nitroblue Tetrazolium; C008922:piperine